|
8 August 2002
Avidex Ltd and ChemOvation Ltd Announce
Research Agreement
Avidex Ltd and ChemOvation Ltd are pleased to
announce that they have entered into a research agreement. Under
the terms of the agreement, full details of which have not been
disclosed, ChemOvation Ltd will be providing Avidex Ltd with medicinal
and synthetic chemistry services and expertise for hit to lead and
lead optimisation work on a fee for service basis.
Avidex Ltd
Avidex is a biotech research and development
company, which was formed as an Oxford University spin-out in July
2000. The Company has programmes for the discovery and development
of products for autoimmune disease, graft rejection and cancer based
on its unique soluble T cell receptor technology.
In particular:
- Avidex is using its T cell receptors in screening
for new chemical entities for autoimmune disease, graft rejection
and cancer
- Avidex intends to develop its Monoclonal
TCRs™ as protein-based cancer targeting agents
Avidex employs 53 staff and is based in Milton
Park, near Oxford, UK. Investors include Advent Venture Partners,
the University of Oxford, Oxford Technology Venture Capital Trust
plc and Quester.
For more information, please go to www.avidex.com
ChemOvation Ltd
ChemOvation is a leading provider of integrated
drug discovery services to the pharmaceutical and biotechnology
sectors. It offers effective, individually tailored solutions to
achieve successful drug candidate realisation. Specialising in:
- Organic chemistry
- Medicinal chemistry
- Computational chemistry
ChemOvation offers clients a wealth of knowledge
and expertise to ensure success in their drug discovery projects.
With the additional facilities of screening, ADME and early toxicology,
ChemOvation provides the complete outsourcing solution for drug
discovery projects.
Further Information:
Dr Keith Menear
ChemOvation Ltd
Foundry Lane
Horsham
West Sussex, RH13 5PX
United Kingdom
Phone +44 (0)1403 248844
Fax +44 (0)1403 248855
Email: keith.menear@chemovation.com
|
